25.80

0.39% 0.10

After Hours: 25.80

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $25.80, with a volume of 3.35M. It is up +0.39% in the last 24 hours and down -7.79% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$25.70

Open:

$25.76

24h Volume:

3.35M

Relative Volume:

1.60

Market Cap:

$11.41B

Revenue:

$2.24B

Net Income/Loss:

$673.24M

P/E Ratio:

229.33

EPS:

0.1125

Net Cash Flow:

$2.67B

1W Performance:

-2.12%

1M Performance:

-7.79%

6M Performance:

-5.39%

1Y Performance:

-3.01%

1-Day Range:

$25.51

$25.94

1-Week Range:

$25.10

$26.41

52-Week Range:

$25.10

$31.66

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1205)

Industry

Biotechnology (682)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX	25.80	11.41B	2.24B	673.24M	2.67B	0.1125
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

Nov 17, 2024

Royalty Pharma plc (NASDAQ:RPRX) Stake Reduced by Amalgamated Bank - MarketBeat

Nov 17, 2024

Nov 16, 2024

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha

Nov 16, 2024

Nov 15, 2024

Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India

Nov 15, 2024

Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat

Nov 15, 2024

Simplify Asset Management Inc. Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 15, 2024

Nov 14, 2024

(RPRX) Technical Data - Stock Traders Daily

Nov 14, 2024

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times

Nov 14, 2024

Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan

Nov 14, 2024

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool

Nov 14, 2024

Nov 13, 2024

Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq

Nov 13, 2024

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St

Nov 13, 2024

Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance

Nov 13, 2024

Syndax shares slide despite pivotal trial success - The Pharma Letter

Nov 13, 2024

Nov 12, 2024

New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 12, 2024

Baillie Gifford & Co. Reduces Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 12, 2024

Royalty Pharma plc (NASDAQ:RPRX) Holdings Cut by Los Angeles Capital Management LLC - MarketBeat

Nov 12, 2024

Nov 11, 2024

Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 11, 2024

Nov 10, 2024

Royalty Pharma Q3 2024 Earnings Preview - MSN

Nov 10, 2024

Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 10, 2024

Nov 09, 2024

Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Nov 09, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat

Nov 09, 2024

Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha

Nov 09, 2024

Nov 08, 2024

Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com

Nov 08, 2024

Nov 07, 2024

Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times

Nov 07, 2024